Increasing Phytochemical-rich Foods and Lactobacillus Probiotics in Men with Low-risk Prostate Cancer-A Randomised, Double-blind, Placebo-controlled Trial [0.03%]
富含植物化学物的食物和乳酸菌对低危前列腺癌男性患者的影响——随机双盲对照试验
Robert J Thomas,Stacey A Kenfield,Madeleine Williams et al.
Robert J Thomas et al.
Men on active surveillance (AS), with prostate cancer, are very interested in dietary strategies that could improve their symptoms and help prevent progression of their disease. In this real-world trial involving 208 men, intake of phytoche...
New TNM Staging System Predicts Progression of Small Renal Masses Under Active Surveillance: A Retrospective Analysis of a Single-center Prospective Series [0.03%]
新的TNM分期系统可预测主动监测下小肾肿瘤的进展情况：单一中心前瞻性队列的回顾性分析
Michele Nicolazzini,Matteo Berra,Paolo De Angelis et al.
Michele Nicolazzini et al.
We validated the newly proposed cT1 classification (new cT1a -tumor size ≤3 cm - vs new cT1b -tumor size >3 cm) for renal masses treated with active surveillance (AS). A prospective AS cohort was retrospectively assessed for growth rate an...
Pretreatment Predictors of Pathologic Failure at 1 year After Focal Therapy for Localized Prostate Cancer [0.03%]
局灶性治疗局部前列腺癌术后1年病理复发的预测指标研究
Anthony Zhang,Nethusan Sivanesan,Preston C Sprenkle
Anthony Zhang
Re: Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, et al. Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab plus Olaparib Versus Abiraterone or Enzalutamide. EurUrol Oncol. In press. https://doi.org/10.1016/j.euo.2025.04.018 [0.03%]
KEYLYNK-010研究中的患者报告结局：派姆单抗联合奥拉帕利 vs 阿比特龙或恩杂鲁胺（即将发表于Eur Urol Oncol）
Isabel Heidegger
Isabel Heidegger
Endoscopic Thulium Laser Ablation with Disitamab Vedotin and Immunotherapy in High-risk Upper Tract Urothelial Carcinoma: A Prospective Pilot Study of a Novel Kidney-sparing Strategy [0.03%]
内镜铥激光消融联合迪塞妥单抗 vedotin 和免疫治疗高危尿路上皮癌的前瞻性试点研究：一种新型保肾策略的研究
Jianjun Ye,Zeyu Chen,Xinyang Liao et al.
Jianjun Ye et al.
Background and objective: Kidney-sparing treatment (KST) is an emerging alternative to radical nephroureterectomy for selected patients with upper tract urothelial carcinoma (UTUC), particularly those with imperative indi...
Downstream Impact of Social Media Use and Variable Quality of Online Information About Prostate Cancer [0.03%]
关于前列腺癌社交媒体使用及其质量各异的在线信息对下游的影响
Stacy Loeb,Mariana Rangel Camacho,Tatiana Sanchez Nolasco et al.
Stacy Loeb et al.
Social media can benefit prostate cancer care through education and empowerment, but also have the potential for exposure to misinformation, leading to adverse health and/or economic impacts for patients and damaging the patient-physician r...
Not Just Longer, But Better Lives: Refining the Measurement of Health-related Quality of Life in Renal Cell Carcinoma [0.03%]
长且优：肾细胞癌相关生命质量测量指标的优化
Lisa M Wintner,Mieke Van Hemelrijck,Christian Beisland
Lisa M Wintner
Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study [0.03%]
肾脏一站式检查评估门诊(COSMIC)：可行性研究
Chiara Re,James P Blackmur,Teele Kuusk et al.
Chiara Re et al.
Background and objective: Our aim was to evaluate the feasibility and outcomes of a one-stop renal mass biopsy (RMB) clinic at which same-day biopsy results were facilitated by the use of confocal microscopy. ...
The Conundrum of Intermediate Risk in Localised Prostate Cancer: One Group, Many Realities [0.03%]
局部前列腺癌Intermediate Risk困境：一个群体，多种现实
Arthur Peyrottes,Guillaume Ploussard,Paul Sargos et al.
Arthur Peyrottes et al.
For intermediate-risk prostate cancer, definitions remain inconsistent and management varies. Greater precision is urgently needed via optimal use of existing tools and integration of emerging innovations to harmonise care and improve outco...
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group [0.03%]
国际膀胱癌组关于 intermediate-risk 低级非肌层浸润性膀胱癌的定义、危险度分层、治疗策略及临床试验设计的指导意见
Roger Li,Patrick J Hensley,Marko Babjuk et al.
Roger Li et al.
Background and objective: Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease, and standardized definitions and risk-guided management are critical for appropriate patient care and...